3-bromo-5-(1H-1,2,3-triazol-1-yl)pyridine | 1354217-85-8

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 3-bromo-5-(1H-1,2,3-triazol-1-yl)pyridine
• 英文别名: 3-bromo-5-(triazol-1-yl)pyridine
• CAS: 1354217-85-8
• 化学式: C₇H₅BrN₄
• 分子量: 225.047
• InChiKey: XCOOCPCBUZXZJH-UHFFFAOYSA-N

物化性质

• 沸点：
  361.6±52.0 °C(Predicted)
• 密度：
  1.79±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-bromo-5-(1H-1,2,3-triazol-1-yl)pyridine 、 生成 4-morpholin-4-yl-N-{5-[5-(1H-1,2,3-triazol-1-yl)pyridin-3-yl]-1,3-thiazol-2-yl}pyridin-2-amine
  参考文献：
  名称：

  Pyridyl aminothiazoles as potent Chk1 inhibitors: Optimization of cellular activity

  摘要：

  Translation of significant biochemical activity of pyridyl aminothiazole class of Chk1 inhibitors into functional CEA potency required analysis and adjustment of both physical properties and kinase selectivity profile of the series. The steps toward optimization of cellular potency included elimination of CDK7 activity, reduction of molecular weight and polar surface area and increase in lipophilicity of the molecules in the series. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.120
• 作为产物：
  描述：

  1H-1,2,3-三氮唑 、 3,5-二溴吡啶 在 caesium carbonate 作用下， 以 2-甲基四氢呋喃 为溶剂， 以9.47 %的产率得到3-bromo-5-(1H-1,2,3-triazol-1-yl)pyridine
  参考文献：
  名称：

  [EN] METTL3 INHIBITOR COMPOUND
  [FR] COMPOSÉ INHIBITEUR DE METTL3
  [ZH] METTL3抑制剂化合物

  摘要：

  提供了一类METTL3抑制剂化合物及其在制备抑制METTL3类药物中的用途，为临床上筛选和/或制备与METTL3活性相关的疾病的药物提供了一种新的选择。

  公开号：

  WO2023104209A1

文献信息

• Nicotinamide derivative or salt thereof
  申请人：Fujiwara Hideyasu

  公开号：US08772320B2

  公开（公告）日：2014-07-08

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种具有优异Syk抑制活性的化合物和药物组合物。本发明提供了以下式子（I）所表示的烟酰胺衍生物（其中R1表示卤素原子；R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基，每个都可以选择性地具有至少一个取代基；R3表示芳基或杂环基，每个都可以选择性地具有至少一个取代基；R4和R5各自独立地表示氢原子；且R2和R4可以与它们结合的氮原子一起选择性地形成一个带有至少一个取代基的环状氨基团）或其盐，以及用于治疗Syk相关疾病的药物组合物，其包括该烟酰胺衍生物或其盐。
• NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
  申请人：FUJIWARA Hideyasu

  公开号：US20130116430A1

  公开（公告）日：2013-05-09

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物（其中R1表示卤素原子；R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基，每种均可选地具有至少一个取代基；R3表示芳基或杂环基，每种均可选地具有至少一个取代基；R4和R5各自独立地表示氢原子；且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团）或其盐，并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
• NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
  申请人：FUJIFILM Corporation

  公开号：EP2589592B1

  公开（公告）日：2018-08-22
• US8772320B2
  申请人：——

  公开号：US8772320B2

  公开（公告）日：2014-07-08
• US8809371B2
  申请人：——

  公开号：US8809371B2

  公开（公告）日：2014-08-19